OX2 Therapeutics, Inc. — Form D
OX2 Therapeutics, Inc. of Minneapolis, MN, a company, filed a Form D exempt-offering notice with the SEC on 2020-09-22. The offering totals $750K, of which $649K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-09-22
- Form: D
- Accession: 0001437749-20-019981
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $750K
- Amount sold: $649K
- Remaining: $101K
- Investors: 15
- Date of first sale: 2020-08-20
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-375949
Issuer
- Name: OX2 Therapeutics, Inc.
- CIK: 0001704490
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 1621 E. Hennepin Avenue, Minneapolis, MN, 55414
- Phone: 612-309-7653
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Andrea Hunt | Director | Minneapolis, MN |
| Christopher Moertel | Director | Minneapolis, MN |
| Ben Oehler | Director | Minneapolis, MN |
| Mike Olin | Director | Minneapolis, MN |
| Rob Parish | Director | Minneapolis, MN |
| Jeff Liter | Executive Officer | Minneapolis, MN |
| Christopher Moertel | Executive Officer | Minneapolis, MN |
| Mike Olin | Executive Officer | Minneapolis, MN |
| Jeff Liter | Promoter | Minneapolis, MN |
| Sumant Dhawan | Director | Mound, MN |
| Sumant Dhawan | Executive Officer | Mound, MN |
| Thomas Martinson | Director | Mound, MN |
Other filings by this issuer (1)
More